Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News PharmaCyte Biotech Inc PMCB

Healthcare Biotechnology
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PMCB)

PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.

Business Wire November 15, 2023

Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech

GlobeNewswire November 15, 2023

PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology

Business Wire October 31, 2023

PharmaCyte Biotech Announces Final Results of Tender Offer

Business Wire June 15, 2023

PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share

Business Wire May 11, 2023

PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan

Business Wire February 2, 2023

PharmaCyte Biotech Board of Directors Announces Business Review Committee to Evaluate Opportunities to Optimize Shareholder Value

GlobeNewswire October 7, 2022

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Business Wire August 15, 2022

PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent Solicitation

Business Wire July 28, 2022
View More News ››

Opinion & Analysis (NDAQ:PMCB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PMCB)

PMCB - YOU SHOULD HAVE IN YOUR WATCH LIST

<< View Post To Watch Video >>
HDavis - September 9, 2021

🎉🎉FSD Pharma Inc CEO Anthony Durkacz Interview✨🎉🎉

<< View Post To Watch Video >>
Monique9987 - August 25, 2021

🎉🎉🎉FSD Pharma (HUGE) CEO Interview ✨🎉📣📽✨🎉🎉🎉

<< View Post To Watch Video >>
Monique9987 - August 25, 2021

📢📢📣📣📺FSD Pharma Inc CEO Anthony Durkacz (Nasdaq: HUGE)

<< View Post To Watch Video >>
MarvieJohanna - August 23, 2021

FSD Pharma Inc CEO Anthony Durkacz (Nasdaq: HUGE)(CSE:HUGE)

<< View Post To Watch Video >>
ElaineSwiss95 - August 19, 2021

Reason For Sudden Surge ???

Does anyone have any insight regarding the recent surge in SP?  Obviously it is a good thing. That said, had I been given some...
frm10328 - January 8, 2021
View more Bullboard ››

Bitcoin Well Inc

Bitcoin Well Inc

Bitcoin Well Inc. is a Canada-based company engaged in the non-custodial fintech business, which future-proofs money by ...
View More »